Exciting New Data on Rina-S Treatment for Ovarian Cancer Patients

Media Release COPENHAGEN, Denmark; September 15, 2024

Genmab A/S (Nasdaq: GMAB) has announced promising results from a Phase 1/2 study of rinatabart sesutecan (Rina-S) in patients with ovarian cancer. The treatment showed an encouraging response rate in heavily pretreated patients, with responses observed across different levels of FRα expression.

Phase 3 Trial Underway

The Phase 3 trial will further evaluate the safety and efficacy of Rina-S at a dose of 120 mg/m2 in patients with advanced ovarian cancer. The study aims to build on the positive results seen in the earlier phases of research.

The investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC) demonstrated a confirmed objective response rate (ORR) of 50.0% in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W). This is a significant development in the search for effective treatments for ovarian cancer.

The data from this study represent a step forward in the understanding of how Rina-S can benefit patients with ovarian cancer, regardless of their FRα expression levels. The potential for a new treatment option for these patients is an exciting prospect in the field of oncology.

How will this impact me?

If you are a patient with advanced ovarian cancer, the promising results of the Rina-S treatment could offer you a new and effective option for managing your disease. The Phase 3 trial will provide further information on the safety and efficacy of this treatment, potentially opening up new avenues for personalized care.

How will this impact the world?

The development of effective treatments for ovarian cancer has the potential to impact the world by improving outcomes for patients and reducing the burden of this disease on healthcare systems. As research into Rina-S and other targeted therapies continues to advance, we may see significant progress in the treatment of ovarian cancer globally.

Conclusion

The new data on Rina-S treatment for ovarian cancer patients is a significant advancement in the field of oncology. The promising results from the Phase 1/2 study offer hope for patients facing this challenging disease, and the ongoing Phase 3 trial holds the potential to further improve outcomes and quality of life for those affected by ovarian cancer. As research into targeted therapies continues to evolve, we can look forward to more effective and personalized treatments for cancer patients in the future.